Operaciones vTv Therapeutics Inc. - VTVT CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.06 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 0.76 |
| Abrir* | 0.74 |
| Cambio de 1 año* | 19.35% |
| Rango del día* | 0.73 - 0.76 |
| Rango de 52 semanas | 0.38-1.40 |
| Volumen medio (10 días) | 66.30K |
| Volumen medio (3 meses) | 2.25M |
| Capitalización de mercado | 81.05M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 104.58M |
| Ingresos | 2.02M |
| EPS | -0.26 |
| Dividendo (Rendimiento %) | N/A |
| Beta | -1.17 |
| Próxima fecha de resultados | May 10, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 0.73 | -0.01 | -1.35% | 0.74 | 0.76 | 0.73 |
| Mar 21, 2023 | 0.76 | 0.02 | 2.70% | 0.74 | 0.76 | 0.74 |
| Mar 20, 2023 | 0.74 | 0.01 | 1.37% | 0.73 | 0.75 | 0.73 |
| Mar 17, 2023 | 0.74 | 0.00 | 0.00% | 0.74 | 0.75 | 0.72 |
| Mar 16, 2023 | 0.77 | 0.01 | 1.32% | 0.76 | 0.77 | 0.75 |
| Mar 15, 2023 | 0.77 | 0.00 | 0.00% | 0.77 | 0.79 | 0.77 |
| Mar 14, 2023 | 0.77 | 0.03 | 4.05% | 0.74 | 0.77 | 0.74 |
| Mar 13, 2023 | 0.74 | 0.04 | 5.71% | 0.70 | 0.76 | 0.68 |
| Mar 10, 2023 | 0.69 | -0.08 | -10.39% | 0.77 | 0.77 | 0.67 |
| Mar 9, 2023 | 0.78 | -0.04 | -4.88% | 0.82 | 0.82 | 0.77 |
| Mar 8, 2023 | 0.82 | -0.08 | -8.89% | 0.90 | 0.90 | 0.81 |
| Mar 7, 2023 | 0.86 | -0.01 | -1.15% | 0.87 | 0.92 | 0.85 |
| Mar 6, 2023 | 0.91 | 0.02 | 2.25% | 0.89 | 0.92 | 0.79 |
| Mar 3, 2023 | 0.76 | -0.01 | -1.30% | 0.77 | 0.77 | 0.75 |
| Mar 2, 2023 | 0.77 | -0.04 | -4.94% | 0.81 | 0.81 | 0.76 |
| Mar 1, 2023 | 0.79 | 0.00 | 0.00% | 0.79 | 0.80 | 0.78 |
| Feb 28, 2023 | 0.79 | 0.04 | 5.33% | 0.75 | 0.79 | 0.75 |
| Feb 27, 2023 | 0.75 | -0.04 | -5.06% | 0.79 | 0.80 | 0.75 |
| Feb 24, 2023 | 0.78 | -0.01 | -1.27% | 0.79 | 0.79 | 0.78 |
| Feb 23, 2023 | 0.82 | -0.01 | -1.20% | 0.83 | 0.83 | 0.81 |
vTv Therapeutics Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos totales | 4.005 | 6.414 | 2.764 | 12.434 | 0.291 |
| Ingresos | 4.005 | 6.414 | 2.764 | 12.434 | 0.291 |
| Gastos totales de explotación | 25.667 | 18.266 | 23.656 | 32.258 | 50.973 |
| Gastos de venta/general/administración Gastos, total | 11.443 | 7.251 | 8.537 | 9.223 | 11.333 |
| Investigación y desarrollo | 12.624 | 11.015 | 15.119 | 23.035 | 39.64 |
| Ingresos de explotación | -21.662 | -11.852 | -20.892 | -19.824 | -50.682 |
| Ingresos por intereses (gastos), netos No operativos | -0.011 | -0.68 | -1.774 | -3.229 | -2.975 |
| Otros, netos | 4.057 | -0.27 | 0.828 | -0.592 | -0.19 |
| Ingresos netos antes de impuestos | -17.616 | -12.802 | -21.838 | -23.645 | -53.847 |
| Ingresos netos después de impuestos | -17.731 | -12.802 | -21.938 | -23.845 | -48.8 |
| Intereses menores | 4.744 | 4.303 | 8.894 | 15.934 | 38.503 |
| Beneficio neto antes de partidas extra. Elementos | -12.987 | -8.499 | -13.044 | -7.911 | -10.297 |
| Ingresos netos | -12.987 | -8.499 | -13.044 | -7.911 | -16.144 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -12.987 | -8.499 | -17.913 | -8.65 | -10.297 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -12.987 | -8.499 | -17.913 | -8.65 | -16.144 |
| Beneficio neto diluido | -12.987 | -8.499 | -17.913 | -8.65 | -16.144 |
| Promedio ponderado de acciones diluidas | 60.7326 | 47.1379 | 30.292 | 12.4492 | 9.69325 |
| BPA diluido sin partidas extraordinarias | -0.21384 | -0.1803 | -0.59134 | -0.69482 | -1.06229 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| BPA normalizado diluido | -0.19671 | -0.1803 | -0.59134 | -0.69482 | -1.06229 |
| Total de partidas extraordinarias | -5.847 | ||||
| Total Adjustments to Net Income | 0 | -4.869 | -0.739 | ||
| Gastos (ingresos) extraordinarios | 1.6 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Ingresos totales | 2 | 0.009 | 3 | 0.009 | 0.987 |
| Ingresos | 2 | 0.009 | 3 | 0.009 | 0.987 |
| Gastos totales de explotación | 8.481 | 11.118 | 4.603 | 4.679 | 5.267 |
| Gastos de venta/general/administración Gastos, total | 5.348 | 5.716 | 2.221 | 2.242 | 2.164 |
| Investigación y desarrollo | 3.133 | 5.402 | 2.382 | 2.437 | 3.103 |
| Ingresos de explotación | -6.481 | -11.109 | -1.603 | -4.67 | -4.28 |
| Ingresos por intereses (gastos), netos No operativos | -0.001 | -0.006 | -0.006 | 0 | 0.001 |
| Otros, netos | -2.742 | 1.632 | 0.244 | 3.829 | -1.648 |
| Ingresos netos antes de impuestos | -9.224 | -9.483 | -1.365 | -0.841 | -5.927 |
| Ingresos netos después de impuestos | -9.424 | -9.483 | -1.465 | -0.841 | -5.942 |
| Intereses menores | 2.417 | 2.432 | 0.378 | 0.233 | 1.701 |
| Beneficio neto antes de partidas extra. Elementos | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
| Ingresos netos | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
| Beneficio neto diluido | -7.007 | -7.051 | -1.087 | -0.608 | -4.241 |
| Promedio ponderado de acciones diluidas | 66.9428 | 66.719 | 61.0733 | 58.6151 | 56.4725 |
| BPA diluido sin partidas extraordinarias | -0.10467 | -0.10568 | -0.0178 | -0.01037 | -0.0751 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.10467 | -0.10568 | -0.0178 | -0.01037 | -0.0751 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 15.621 | 7.215 | 2.838 | 3.473 | 20.362 |
| Efectivo e inversiones a corto plazo | 13.415 | 5.747 | 1.777 | 1.683 | 11.758 |
| Efectivo y Equivalentes | 13.415 | 5.747 | 1.777 | 1.683 | 11.758 |
| Total deudores, neto | 0.057 | 0.158 | 0.005 | 0 | 8 |
| Accounts Receivable - Trade, Net | 0.057 | 0.158 | 0.005 | 0 | 8 |
| Prepaid Expenses | 1.914 | 0.939 | 0.806 | 0.666 | 0.442 |
| Total Assets | 25.474 | 14.789 | 9.266 | 8.559 | 27.917 |
| Property/Plant/Equipment, Total - Net | 0.68 | 0.849 | 1.004 | 0.07 | 0.283 |
| Property/Plant/Equipment, Total - Gross | 0.985 | 1.065 | 1.152 | 8.501 | 9.399 |
| Accumulated Depreciation, Total | -0.305 | -0.216 | -0.148 | -8.431 | -9.116 |
| Other Long Term Assets, Total | 0 | 2.944 | 2.536 | 4.792 | |
| Total Current Liabilities | 8.498 | 6.39 | 13.381 | 18.837 | 26.929 |
| Accounts Payable | 1.876 | 1.925 | 2.232 | 2.899 | 2.269 |
| Payable/Accrued | |||||
| Accrued Expenses | 6.331 | 4.35 | 4.946 | 4.803 | 11.632 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.035 | 0.031 | 0.031 | 1.752 | 8.757 |
| Total Liabilities | 35.214 | 94.891 | 58.289 | 91.412 | 178.964 |
| Total Long Term Debt | 0 | 0 | 0 | 6.33 | 15.316 |
| Long Term Debt | 0 | 6.33 | 15.316 | ||
| Minority Interest | 24.962 | 83.895 | 40.183 | 62.482 | 131.44 |
| Other Liabilities, Total | 1.754 | 4.606 | 4.725 | 3.763 | 5.279 |
| Total Equity | -9.74 | -80.102 | -49.023 | -82.853 | -151.047 |
| Common Stock | 0.901 | 0.773 | 0.641 | 0.435 | 0.329 |
| Additional Paid-In Capital | 238.193 | 209.161 | 183.858 | 150.595 | 127.682 |
| Retained Earnings (Accumulated Deficit) | -248.834 | -290.036 | -233.522 | -233.883 | -279.058 |
| Total Liabilities & Shareholders’ Equity | 25.474 | 14.789 | 9.266 | 8.559 | 27.917 |
| Total Common Shares Outstanding | 90.0366 | 77.1449 | 64.0127 | 43.4413 | 32.8125 |
| Other Current Assets, Total | 0.235 | 0.371 | 0.25 | 1.124 | 0.162 |
| Long Term Investments | 9.173 | 6.725 | 2.48 | 2.48 | 2.48 |
| Current Port. of LT Debt/Capital Leases | 0.256 | 0.084 | 6.172 | 9.383 | 4.271 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 13.612 | 15.621 | 22.171 | 11.272 | 9.221 |
| Efectivo e inversiones a corto plazo | 12.138 | 13.415 | 19.566 | 10.835 | 8.449 |
| Efectivo y Equivalentes | 12.138 | 13.415 | 19.566 | 10.835 | 8.449 |
| Total deudores, neto | 0.057 | 0.057 | 0.928 | 0 | 0.002 |
| Accounts Receivable - Trade, Net | 0.057 | 0.057 | 0.928 | 0 | 0.002 |
| Prepaid Expenses | 1.387 | 2.049 | 1.574 | 0.313 | 0.71 |
| Other Current Assets, Total | 0.03 | 0.1 | 0.103 | 0.124 | 0.06 |
| Total Assets | 20.185 | 25.474 | 31.434 | 21.66 | 16.754 |
| Property/Plant/Equipment, Total - Net | 0.634 | 0.68 | 0.724 | 0.766 | 0.808 |
| Long Term Investments | 5.939 | 9.173 | 8.539 | 9.622 | 6.725 |
| Total Current Liabilities | 12.7 | 8.498 | 5.51 | 5.059 | 5.162 |
| Payable/Accrued | 12.474 | 8.023 | 4.663 | 4.855 | 4.965 |
| Accrued Expenses | 0.191 | 0.184 | 0.176 | 0.169 | 0.162 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.256 | 0.636 | 0 | 0 |
| Other Current Liabilities, Total | 0.035 | 0.035 | 0.035 | 0.035 | 0.035 |
| Total Liabilities | 28.278 | 35.214 | 52.979 | 69.483 | 73.029 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 14.367 | 24.962 | 44.61 | 60.19 | 62.647 |
| Other Liabilities, Total | 1.211 | 1.754 | 2.859 | 4.234 | 5.22 |
| Total Equity | -8.093 | -9.74 | -21.545 | -47.823 | -56.275 |
| Common Stock | 0.901 | 0.901 | 0.897 | 0.834 | 0.808 |
| Additional Paid-In Capital | 238.669 | 238.193 | 236.557 | 224.457 | 217.647 |
| Retained Earnings (Accumulated Deficit) | -247.663 | -248.834 | -258.999 | -273.114 | -274.73 |
| Total Liabilities & Shareholders’ Equity | 20.185 | 25.474 | 31.434 | 21.66 | 16.754 |
| Total Common Shares Outstanding | 90.0366 | 90.0366 | 89.565 | 83.2878 | 80.6658 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -17.731 | -12.802 | -21.938 | -23.845 | -54.647 |
| Efectivo de actividades de explotación | -19.308 | -18 | -23.018 | -26.856 | -44.56 |
| Efectivo de actividades de explotación | 0.089 | 0.094 | 0.039 | 0.218 | 0.197 |
| Partidas no monetarias | -1.701 | -2.586 | 0.935 | 4.316 | 4.853 |
| Intereses pagados en efectivo | 0.011 | 0.623 | 1.295 | 2.276 | 2.064 |
| Cambios en el capital circulante | 0.035 | -2.706 | -2.054 | -7.545 | 5.037 |
| Efectivo de actividades de inversión | 0 | 0 | 0.242 | 0.007 | -0.025 |
| Gastos de capital | 0 | 0 | -0.07 | -0.005 | -0.057 |
| Otras partidas de flujo de caja de inversión, total | 0 | 0 | 0.312 | 0.012 | 0.032 |
| Efectivo procedente de actividades de financiación | 26.976 | 19.47 | 22.87 | 16.612 | 7.5 |
| Elementos de flujo de caja de financiación | 0 | 0 | |||
| Emisión (retiro) de acciones, neto | 26.804 | 24.426 | 32.943 | 21.5 | 0 |
| Emisión (amortización) de deuda, neta | 0.172 | -4.956 | -10.073 | -4.888 | 7.5 |
| Variación neta de la tesorería | 7.668 | 1.47 | 0.094 | -10.237 | -37.085 |
| Cash Taxes Paid | 0.115 | 0 | 0.1 | 1 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.424 | -17.731 | -8.248 | -6.783 | -5.942 |
| Cash From Operating Activities | -1.021 | -19.308 | -12.891 | -9.297 | -5.299 |
| Cash From Operating Activities | 0.023 | 0.089 | 0.067 | 0.045 | 0.023 |
| Non-Cash Items | 3.218 | -1.701 | -1.063 | -1.292 | 2.084 |
| Changes in Working Capital | 5.162 | 0.035 | -3.647 | -1.267 | -1.464 |
| Cash From Financing Activities | -0.256 | 26.976 | 26.71 | 14.385 | 8.001 |
| Issuance (Retirement) of Stock, Net | 0 | 26.804 | 26.158 | 14.469 | 8.085 |
| Issuance (Retirement) of Debt, Net | -0.256 | 0.172 | 0.552 | -0.084 | -0.084 |
| Net Change in Cash | -1.277 | 7.668 | 13.819 | 5.088 | 2.702 |
| Cash From Investing Activities | 0 | ||||
| Capital Expenditures | 0 | ||||
| Other Investing Cash Flow Items, Total | 0 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| MacAndrews & Forbes Holdings, Inc. | Holding Company | 44.9246 | 36606212 | 87000 | 2022-05-31 | LOW |
| G42 Investments AI Holdings RSC, Ltd. | Corporation | 12.7465 | 10386274 | 10386274 | 2022-05-31 | LOW |
| Medpace Investors, L.L.C. | Corporation | 6.6241 | 5397529 | 5397529 | 2022-08-16 | LOW |
| Samsara BioCapital, LLC | Venture Capital | 2.0072 | 1635509 | 0 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1531 | 939623 | 653 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3551 | 289347 | -653 | 2022-12-31 | LOW |
| Veritable, L.P. | Investment Advisor/Hedge Fund | 0.2981 | 242937 | 222032 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1654 | 134745 | 0 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 0.0786 | 64078 | -13261 | 2022-12-31 | HIGH |
| Fry (John Anthony) | Individual Investor | 0.0749 | 61000 | 61000 | 2022-11-29 | LOW |
| Nelson (Rich S) | Individual Investor | 0.0736 | 60000 | 0 | 2022-04-04 | |
| HBKS Wealth Advisors | Investment Advisor | 0.0708 | 57694 | 57694 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0659 | 53660 | -185 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.06 | 48860 | 15848 | 2022-12-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0498 | 40577 | 0 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.0467 | 38052 | 5667 | 2022-12-31 | HIGH |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.041 | 33442 | 0 | 2022-12-31 | LOW |
| Simon Quick Advisors, LLC | Investment Advisor | 0.0368 | 30000 | 0 | 2022-12-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.0332 | 27018 | 0 | 2022-12-31 | LOW |
| Kozlov (Hersh) | Individual Investor | 0.0307 | 25000 | 0 | 2022-04-04 |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
vTv Therapeutics Inc. Company profile
Sobre vTv Therapeutics Inc
vTv Therapeutics Inc. es una empresa farmacéutica en fase clínica que se dedica al descubrimiento y desarrollo de candidatos a fármacos de moléculas pequeñas de administración oral. Está desarrollando un programa para el tratamiento de la diabetes tipo I TTP399 y para la psoriasis HPP737. El TTP399 es un activador de la glucoquinasa (GKA) selectivo para el hígado, de pequeña molécula y administrado por vía oral, que está desarrollando un potencial antidiabético oral para el tratamiento de la diabetes de tipo I. El TTP399 ha completado el estudio SimpliciT-I, un ensayo de fase II en pacientes con diabetes de tipo I como complemento del tratamiento con insulina. La empresa también está llevando a cabo un estudio de fase I de dosis múltiples ascendentes de HPP737, un inhibidor de la fosfodiesterasa tipo IV administrado por vía oral, para evaluar la farmacocinética, la farmacodinámica, la seguridad y la tolerabilidad de HPP737 en voluntarios sanos como parte de su programa contra la psoriasis. Su TTP273 es un agonista del receptor del péptido similar al glucagón I (GLP-1), de molécula pequeña, que se está evaluando para el tratamiento de la diabetes mellitus de tipo II.
| Industry: | Bio Therapeutic Drugs |
3980 Premier Dr
Suite 310
HIGH POINT
NORTH CAROLINA 27265
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com